All In Biotech

Free tool

FAERS Monitor: Epclusa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208341 or its brand name (Epclusa, Sofosbuvir, Velpatasvir). Reports on generic versions are filed under their own applications.

Reports

12,830

Serious

3,897

30% of reports

Hospitalization

1,446

Death reported

592

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue2,628
  • headache2,218
  • nausea1,178
  • diarrhoea664
  • drug ineffective558
  • insomnia514
  • hepatitis c413
  • treatment failure337
  • vomiting330
  • death312
  • dizziness287
  • rash259
  • product dose omission issue248
  • abdominal discomfort239
  • intentional dose omission218

Reports by year received

View as table
YearReports
2016400
20172,137
20182,222
20192,663
20201,724
20211,071
2022990
2023570
2024449
2025373
2026231

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,329 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatitis cSignal41358.052.722,314
intentional dose omissionSignal21812.611.12,307
treatment failureSignal3376.76.01,626
headacheSignal2,2185.85.69,081
fatigueSignal2,6285.55.410,138
insomniaSignal5143.22.9769
nauseaSignal1,1782.42.31,039
abdominal discomfortSignal2392.32.1183
diarrhoea6641.71.6191
product dose omission issue2481.41.226
vomiting3301.21.07
rash2591.00.90
dizziness2870.90.81
drug ineffective5580.70.680
death3120.60.590

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.